Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 73

recruiting
3 977
countries
28
conditions
2 105

1 112 trials match your criteria

Huntington's disease

Not recruiting

Study on the Safety and Effects of PTC518 for Patients with Huntington's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:PTC518

Study on the Effect of Dupilumab for Patients with Chronic Rhinosinusitis with Nasal Polyps

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab

Short stature

Not recruiting

Study on the Effects of Somapacitan and Somatropin in Children with Short Stature Born Small for Gestational Age Without Catch-Up Growth by Age 2

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Somapacitan

Myelofibrosis

Not recruiting

Study Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan

Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Cytarabine

Gastric cancer+1

Not recruiting

Study on the Safety and Activity of S095029 and Pembrolizumab for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Sepsis+1

Not recruiting

Study on the Safety and Effectiveness of TIN816 for Patients with Sepsis-Related Acute Kidney Injury

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:TIN816

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Drug Combination for Patients with Advanced AL Amyloidosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab

Hidradenitis

Not recruiting

Study on the Effectiveness of Ianalumab for Treating Moderate to Severe Hidradenitis Suppurativa in Patients

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab

Neoplasm

Not recruiting

Study of Avapritinib for Children with Solid Tumors Linked to KIT or PDGFRA Signaling

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Avapritinib

Myasthenia gravis

Not recruiting

Study on the Safety and Effectiveness of Gefurulimab for Adults with Generalized Myasthenia Gravis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gefurulimab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.